London-listed AstraZeneca shares fell more than 5% on Tuesday after results from the company's lung cancer trials showed that ...

A Phase 3 trial found AstraZeneca's experimental lung cancer drug did not significantly improve patients' overall survival rates.

AstraZeneca’s Imfinzi recently became the first PD-1/L1 inhibitor to deliver a patient survival win in muscle-invasive ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Shares in AstraZeneca dropped nearly 5 per cent on Tuesday after its failure to hit a target in trials for ...

AstraZeneca has paused a late-stage trial of one of the leading COVID-19 vaccine candidates after a suspected serious adverse reaction in a study participant, health news website Stat News ...

AstraZeneca's lung cancer drug datopotamab ... when compared to standard chemotherapy drug docetaxel, according to trial results published Sept. 9 in the Journal of Clinical Oncology.

AstraZeneca shares fell more than 5% Tuesday morning, the biggest one-day drop in seven months, after the British pharmaceutical giant announced disappointing lung cancer drug trial results.

Also Read: AstraZeneca In Trouble For Employee Detentions ... developed by AstraZeneca and Daiichi Sankyo. In the overall trial population, OS results numerically favored datopotamab deruxtecan ...

The TROPION-Lung01 Phase III trial evaluated AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan compared to docetaxel, the current standard of care chemotherapy, in adult patients with ...

and being jointly developed by AstraZeneca and Daiichi Sankyo. In the overall trial population, OS results numerically favored datopotamab deruxtecan compared to docetaxel (12.9 vs. 11.8 months ...